Observational Study of Obstructive Lung Disease (NOVELTY)



Status:Recruiting
Conditions:Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:12 - Any
Updated:2/23/2019
Start Date:July 25, 2016
End Date:May 31, 2021
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.

The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive
lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study
which will recruit patients with a diagnosis, or suspected diagnosis, of asthma and/or
Chronic Obstructive Pulmonary Disease (COPD). Patients will undergo clinical assessments and
receive standard medical care as determined by their treating physician. Patients enrolled in
NOVELTY will be followed up yearly by their treating physician for a total duration of three
years. In addition, patients will be followed up remotely every 3 months. The NOVELTY study
will collect data currently lacking to allow for multinational data collection to fill
regional/local gaps and improve comparability across regions.

The NOVELTY study is a multi-country, multicentre, observational, prospective, longitudinal
cohort study which will include patients with a physician diagnosis, or suspected diagnosis,
of asthma and/or COPD. Patients will undergo clinical assessments and receive standard
medical care as determined by the treating physician. All patients enrolled in the NOVELTY
study will be followed up yearly by their treating physician for a total duration of three
years. In addition, patients are expected to be followed up remotely once every quarter.

It is estimated that approximately 7,700 patients with suspected or primary diagnosis of
asthma and 7,100 patients with suspected or primary diagnosis of COPD will be enrolled by a
diverse set of physicians (e.g. primary care physicians, allergists, pulmonologists) from
community and hospital outpatient settings within the countries targeted for NOVELTY.

Exposure(s):

The NOVELTY study is a longitudinal cohort study which does not involve or study a specific
medicinal product; it will constitute a disease registry. Information about exposure to
treatments as part of routine care will be collected (frequency, treatment, duration).

Sample Size Estimations:

The target minimum number of 100 patients per diagnostic label (asthma or COPD),
physician-assessed severity level and country has been chosen to support many basic local
reimbursement specific requirements with reasonable precision, and to provide large sample
size for scientific questions applicable across severities and countries. Therefore,
considering the targeted countries, it is estimated that approximately 7,700 patients with
asthma and 7,100 patients with COPD will be enrolled.

Statistical Analysis:

After baseline data collection and each annual data collection, data will be summarized for
the population overall and by pre specified subgroups, including by country, demographics,
exposures, symptom history, treatment history, concurrent clinical features, treatment
setting, socioeconomic setting and access to healthcare, where relevant.

Patients' changes regarding their treatment, disease or severity among and other variables
that are observed between baseline and follow-up visits, will also be described.

To identify potential differences in disease diagnosis and severity classifications between
physicians and guidelines, data collected on lung function results, symptom questionnaires,
exacerbation occurrences and medication will allow the formal and consistent classification
of the patients according to relevant international guidelines and other current and future
phenotypic/diagnostic classifications.

Multivariable models will be used to assess the following: the occurrence of exacerbations
and other conditions, including upper and lower Respiratory Tract Infections (RTIs) and their
relationship with clinical outcomes, the relationship between Patient Reported Outcomes (PRO)
and disease control with impact on daily activity and quality of life, and the relationship
between healthcare resource use overall and related to respiratory diseases with disease
severity, clinical outcomes, disease type, etc.

Multivariable analysis techniques will be used to identify phenotypes and endotypes, based on
biomarkers and/or clinical parameters that are associated with differential outcomes for
symptom burden, clinical evolution and healthcare utilisation.

Inclusion Criteria:

- Diagnosis, or suspected diagnosis, of asthma and/or COPD, according to clinician`s
judgment

- Age: 12 years or older (note: in most countries it will only be feasible to include
patients aged 18 years or older)

- Willing and able to sign written, informed consent (or having a responsible, legally
authorised representative acting on patient's behalf)

- Enrolment from an active clinical practice

Exclusion Criteria:

- Patients who participated in any respiratory interventional trial during the 12 months
prior to enrolment or at enrolment

- Patients who, in the opinion of the physician, are unlikely to complete 3 years of
follow-up, e.g. poor literacy, substance abuse, life-threatening co-morbidity

- Patients whose primary respiratory diagnosis (i.e. the condition causing most of their
respiratory symptoms) is not asthma or COPD (however, a co-diagnosis of another
respiratory disease such as bronchiectasis or interstitial lung disease together with
asthma or COPD will be accepted)

In addition, the following are considered criteria for exclusion from the exploratory
genetic research (donation of blood for DNA and RNA analysis)

- Previous allogeneic bone marrow transplant

- Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
genetic sample collection
We found this trial at
54
sites
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Asheboro, NC
Click here to add this to my saved trials
?
mi
from
Atco, NJ
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Bellevue, NE
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Buckley, MI
Click here to add this to my saved trials
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
?
mi
from
Charleston, WA
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
Colorado Springs, Colorado 80910
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dayton, OH
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
?
mi
from
DuBois, PA
Click here to add this to my saved trials
East Providence, Rhode Island 02915
?
mi
from
East Providence, RI
Click here to add this to my saved trials
Fall River, Massachusetts 02720
?
mi
from
Fall River, MA
Click here to add this to my saved trials
?
mi
from
Fargo, ND
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
3056 Hanley Street
Hamtramck, Michigan 48212
?
mi
from
Hamtramck, MI
Click here to add this to my saved trials
?
mi
from
Hazard, KY
Click here to add this to my saved trials
Highland Park, New Jersey 08904
?
mi
from
Highland Park, NJ
Click here to add this to my saved trials
?
mi
from
Hutchinson, KS
Click here to add this to my saved trials
?
mi
from
Lansdale, PA
Click here to add this to my saved trials
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
?
mi
from
Live Oak, TX
Click here to add this to my saved trials
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oakland, CA
Click here to add this to my saved trials
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
?
mi
from
Plantation, FL
Click here to add this to my saved trials
?
mi
from
Providence, RI
Click here to add this to my saved trials
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Rockville Centre, New York 11570
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
?
mi
from
Springfield, IL
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
?
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
?
mi
from
Wooster, OH
Click here to add this to my saved trials